Fei Hua

The First People's Hospital of Changzhou — China

Medicine · Health Sciences

23h-index1.9kcitations83works0.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(13), Computational Drug Discovery Methods(8), Hemophilia Treatment and Research(8), Blood Coagulation and Thrombosis Mechanisms(7), Immune Cell Function and Interaction(7)

Publications83 total

A Tutorial on the Development of a Physiologically Inspired <scp>PKRO</scp> Model for Monoclonal Antibodies
CPT Pharmacometrics & Systems Pharmacology·2025Open Access
Advances in Microneedle Drug Delivery for Obesity: Mechanisms, Applications, and Perspectives
International Journal of Nanomedicine·2025Open Access
A phase III clinical trial of monthly minodronate in the treatment of Chinese postmenopausal women with osteoporosis
Acta Pharmacologica Sinica·2025Open Access
Quantitative Systems Pharmacology Model for Therapies Targeting Aβ and Tau Pathologies in Alzheimer’s Disease
Alzheimer s & Dementia·2024Open Access
1317 A quantitative systems pharmacology model for first-in-human dosing of MDX2001, a multispecific antibody for the treatment of advanced solid tumors
Regular and Young Investigator Award Abstracts·2024Open Access
Industry Perspective on First‐in‐Human and Clinical Pharmacology Strategies to Support Clinical Development of T‐Cell Engaging Bispecific Antibodies for Cancer Therapy
Clinical Pharmacology & Therapeutics·2024· 6 cited
Comparison of dose selection based on target engagement versus inhibition of receptor–ligand interaction for checkpoint inhibitors
CPT Pharmacometrics & Systems Pharmacology·2024· 1 citedOpen Access
Comprehensive Human Quantitative Systems Pharmacology Models for Immuno-Oncology: Enhancing Decision-Making on Target Indications and Combination Strategies for New Drug Development
2024Open Access
A quantitative systems pharmacology (QSP) model to enable prediction of ARIA-E incidence with anti-Aβ monoclonal antibody therapies for Alzheimer’s disease
2024Open Access
Landscape of molecular crosstalk between SARS-CoV-2 infection and cardiovascular diseases: emphasis on mitochondrial dysfunction and immune-inflammation
Journal of Translational Medicine·2023· 13 citedOpen Access
Mechanistic PK/PD modeling to address early-stage biotherapeutic dosing feasibility questions
mAbs·2023· 5 citedOpen Access
A next generation mathematical model for the in vitro to clinical translation of T-cell engagers
Journal of Pharmacokinetics and Pharmacodynamics·2023· 16 cited
Denosumab biosimilar (LY06006) in Chinese postmenopausal osteoporotic women: A randomized, double-blind, placebo-controlled, multicenter phase III study
Journal of Orthopaedic Translation·2022· 16 citedOpen Access
From Cold to Hot: Changing Perceptions and Future Opportunities for Quantitative Systems Pharmacology Modeling in Cancer Immunotherapy
Clinical Pharmacology & Therapeutics·2022· 20 citedOpen Access
Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors
ESMO Open·2022· 34 citedOpen Access
Early Feasibility Assessment: A Method for Accurately Predicting Biotherapeutic Dosing to Inform Early Drug Discovery Decisions
Frontiers in Pharmacology·2022· 8 citedOpen Access
Quantitative systems pharmacology modeling provides insight into inter‐mouse variability of <scp>Anti‐CTLA4</scp> response
CPT Pharmacometrics & Systems Pharmacology·2022· 8 citedOpen Access
Quantitative systems pharmacology model for Alzheimer’s disease to predict the effect of aducanumab on brain amyloid
CPT Pharmacometrics & Systems Pharmacology·2022· 19 citedOpen Access
Abstract 1919: Prediction of systemic cytokine exposure in human after IV administration of oncolytic myxoma virus, using quantitative systems pharmacology modeling
Cancer Research·2021
A systems pharmacology model for gene therapy in sickle cell disease
CPT Pharmacometrics & Systems Pharmacology·2021· 7 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

John M. Burke(10), Joshua F. Apgar(9), Jin‐Song Bian(6), Robert F. Gilmour(4), Zhiyuan Wu(4), Steven Arkin(4), Gail M. Comer(3), Fabio Cataldi(3), Douglas A. Lauffenburger(3), Xiaofei Yan(3), Raibatak Das(3), Lucia Wille(3), Diana H. Marcantonio(3), Alison Betts(3), Andrew Matteson(3), Julián Panés(2), Michelle Hinz(2), Karen Page(2), Tara McDonnell Moorehead(2), Zhizhong Xie(2)